Epigral Ltd Falls 10.37%: Six-Day Slide Amid Profit Declines and Rising Costs

5 January: Sharp Decline to 52-Week Low Amid Elevated Volatility

Epigral Ltd’s stock opened the week under intense selling pressure, closing at Rs.1,189.40, down 4.70% on the day. The stock hit an intraday 52-week low of Rs.1,157.35, marking a 7.43% intraday drop and signalling heightened volatility with a weighted average price volatility of 5.39%. This decline extended a two-day losing streak, with the stock falling 8.21% cumulatively. The stock underperformed its specialty chemicals sector by 7.64% and the broader market, as the Sensex declined only 0.18%.

Technically, the stock traded below all major moving averages (5-day through 200-day), indicating sustained bearish momentum. The Mojo Score stood at 31.0 with a Sell rating, downgraded from Strong Sell on 26 December 2025, reflecting cautious market sentiment.

6 January: Continued Downtrend Extends Losses to 8.62% Over Three Days

The downtrend persisted on 6 January, with Epigral’s shares falling 1.94% to close at Rs.1,166.30. The stock touched a fresh 52-week low of Rs.1,150.75 during the session, extending the three-day losing streak to an 8.62% decline. The stock again underperformed the Sensex, which fell 0.19%, and lagged its sector by 2.51%. Despite the broader market’s resilience near its 52-week high, Epigral’s technical positioning remained weak, trading below all key moving averages.

Financially, the company’s operating profit has contracted at an annualised rate of 5.49% over five years, with recent quarterly results showing a 45.2% drop in profit before tax and a 52.6% decline in profit after tax. Interest expenses surged 37.3% over nine months, adding to financial strain.

7 January: Stock Hits Rs.1,150, Marking Fourth Consecutive Day of Decline

On 7 January, Epigral’s shares declined marginally by 0.90% to Rs.1,155.80, touching a new 52-week low of Rs.1,150. The stock underperformed its sector by 1.84%, continuing the trend of relative weakness. The broader market showed mixed signals, with the Sensex down 0.32%. Over the past year, Epigral’s stock has lost 36.84%, contrasting with the Sensex’s 8.42% gain.

Financial pressures intensified as interest expenses surged 286.41% to Rs.45.21 crores over six months, while quarterly profit after tax fell 52.6%. Despite these challenges, the company maintains a strong return on capital employed (ROCE) of 23.19% and a low Debt to EBITDA ratio of 1.34 times, indicating sound capital efficiency and manageable leverage.

8 January: Fifth Day of Losses Sees Stock Fall to Rs.1,143.5

Epigral’s downtrend extended to a fifth consecutive day on 8 January, with the stock closing at Rs.1,138.15, down 1.53%. The stock hit a fresh 52-week low of Rs.1,143.5, underperforming its sector by 1.42%. The Sensex declined 1.41%, showing relative market weakness. The company’s operating profit margin to net sales ratio remained subdued at 22.53%, reflecting margin pressures.

Valuation metrics suggest the stock is trading at a discount, with an enterprise value to capital employed ratio of 2.1 and a low PEG ratio of 0.4, despite the negative price trend. Promoters continue to hold majority ownership, providing stability amid market volatility.

9 January: Week Closes at Rs.1,118.60, Marking Sixth Consecutive Loss

Epigral Ltd’s stock closed the week at Rs.1,118.60 on 9 January, a fresh 52-week low and a 1.72% decline on the day. This marked six consecutive sessions of losses, with the stock shedding approximately 9.8% over this period. Despite this, the stock marginally outperformed its sector on the day by 0.57%. The Sensex closed marginally higher at 84,188.22, demonstrating broader market resilience.

Long-term underperformance remains stark, with the stock down 38.17% over the past year versus the Sensex’s 8.45% gain. The company’s financials continue to show pressure, with a 52.6% decline in quarterly PAT and a 286.41% increase in interest expenses over six months. Operating profit margins remain low at 22.53%, though capital efficiency remains strong with a ROCE of 23.19% and manageable leverage.

Daily Price Performance: Epigral Ltd vs Sensex

Conclusion

Epigral Ltd’s stock performance over the week ending 9 January 2026 highlights a sustained downtrend amid challenging financial conditions and market sentiment. The stock’s multiple 52-week lows and consistent underperformance relative to the Sensex and its sector peers underscore persistent pressures on profitability and valuation. Despite strong capital efficiency and manageable debt levels, the sharp decline in quarterly profits and rising interest expenses have weighed heavily on investor confidence.

While the broader market has shown resilience near its 52-week highs, Epigral’s share price remains firmly below all key moving averages, signalling continued bearish momentum. The company’s current Mojo Score of 31.0 and Sell rating reflect this cautious outlook. Investors will likely monitor upcoming financial results and sector developments closely to assess any potential shifts in the stock’s trajectory.

Unlock special upgrade rates for a limited period. Start Saving Now →